Support Care Cancer DOI 10.1007/s00520-014-2534-3
ORIGINAL ARTICLE
Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer Madoka Kimura & Tateaki Naito & Hirotsugu Kenmotsu & Tetsuhiko Taira & Kazushige Wakuda & Takuya Oyakawa & Yasushi Hisamatsu & Takaaki Tokito & Hisao Imai & Hiroaki Akamatsu & Akira Ono & Kyoichi Kaira & Haruyasu Murakami & Masahiro Endo & Keita Mori & Toshiaki Takahashi & Nobuyuki Yamamoto
Received: 7 August 2014 / Accepted: 17 November 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Purpose Cancer cachexia (CC) is commonly seen in advanced lung cancer patients and associated with poor prognosis. However, little is known about CC that develops during chemotherapy. We evaluated the prognostic impact of CC and skeletal muscle wasting that develops during the course of chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Methods The clinical data of 134 newly diagnosed NSCLC patients were retrospectively reviewed. CC was defined as a body weight loss >5 or >2 % in patients with a body mass index of
ORIGINAL ARTICLE
Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer Madoka Kimura & Tateaki Naito & Hirotsugu Kenmotsu & Tetsuhiko Taira & Kazushige Wakuda & Takuya Oyakawa & Yasushi Hisamatsu & Takaaki Tokito & Hisao Imai & Hiroaki Akamatsu & Akira Ono & Kyoichi Kaira & Haruyasu Murakami & Masahiro Endo & Keita Mori & Toshiaki Takahashi & Nobuyuki Yamamoto
Received: 7 August 2014 / Accepted: 17 November 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Purpose Cancer cachexia (CC) is commonly seen in advanced lung cancer patients and associated with poor prognosis. However, little is known about CC that develops during chemotherapy. We evaluated the prognostic impact of CC and skeletal muscle wasting that develops during the course of chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Methods The clinical data of 134 newly diagnosed NSCLC patients were retrospectively reviewed. CC was defined as a body weight loss >5 or >2 % in patients with a body mass index of
